Tenofovir as a drug of choice for the chronic hepatitis B treatment
|
|
- Gilbert Stewart
- 6 years ago
- Views:
Transcription
1 EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis B treatment K. Zhdanov
2 Viread Clinical Trials Span All Populations of Chronic HBV Patients HBV Stages Quiescent Disease Treatment Naive Treatment Experienced Decompensated Liver Disease Patient Population Adults/Peds Peds Adolescents Adults Decomp. Liver Dz Liver Transplant Acute infection Chronic Infection Cirrhosis OLT Death Study 101 Immune Tolerant Study 144 Pediatrics 2-12 yr Study 115 Adolesc yr Studies 102 & 103 Tx Naïve Adults (HBeAg+, HBeAg-) Study 121 LAM- Resistant Study 106 ADV- Exper. Study 108 Decomp. Disease Study 107 Transplant Gilead Studies TDF vs. TVD TDF vs. PLB TDF vs. PLB TDF vs. ADV; OL TDF (8 yr) TDF vs. TVD TDF vs. TVD TDF vs. TDV vs. ETV TVD + HBIG vs. TVD AASLD 2012 (final) Start Q EASL 2012 (72 wk) AASLD 2011, APASL 2012 (240 wk) AASLD 2012 (96 wk) AASLD 2010 (final) AASLD 2012 (final) Liver Transpl. (final)
3
4 Studies 102/103 Study designs Phase 3, randomised, double-blind, placebo-controlled trials in which adult patients received open-label tenofovir disoproxil fumarate (TDF) after Year 1 for a study duration of up to 8 years Chronic HBV patients (HBeAgand HBeAg+) N=641 TDF 300 mg (n=250, 176) ADV 10 mg (n=125, 90) Open-Label TDF 300 mg QD, N=585 Study Year Liver Biopsies Patients had the option to add FTC at the discretion of the investigator if confirmed HBV DNA 400 copies/ml at Week 72 or beyond Neither Truvada (TVD = TDF + FTC) or emtricitabine (FTC) are licensed for use to treat CHB Marcellin P, et al. AASLD 2012; Boston. #374. Jacobson I, et al. AASLD 2012; Boston. #411.
5 Studies 102/103 Virologic Suppression at Year 6 Response HBeAg- Patients (Study 102) HBeAg+ Patients (Study 103) Year 5 Year 6 Year 5 Year 6 HBV DNA < 400 copies/ml Intent-to-treat *, % (n/n) 83 (291/350) 81 (281/345) 65 (160/248) 63 (157/251) HBV DNA < 400 copies/ml On treatment, % (n/n) 99 (292/295) 99.6 (283/284) 97 (170/175) 99 (167/169) * LTE-TDF (missing = failure/addition of FTC = failure) Observed (missing = excluded/addition of FTC = included) 80% of 585 patients entering the open-label phase remained on study at Year 6; 73% of enrolled patients remained on study HBeAg loss/seroconversion rates of 50% and 37%, respectively, through 6 years 11% of HBeAg+ patients had confirmed HBsAg loss (8% with seroconversion) No resistance to TDF was detected through 6 years Marcellin P, et al. AASLD 2012; Boston. #374. Neither Truvada (TVD = TDF + FTC) or emtricitabine (FTC) are licensed for use to treat CHB
6 Studies 102/103 Virologic Suppression at Year 6
7 Studies 102/103 Virologic Suppression at Year 6
8 Studies 102/103 Resistance Results Through Year 5 No resistance to TDF was detected through 6 years A. B. Number of Subjects (9%) 389 (91%) 24 (6%) 364 (85%) 13* (3%) Year 348 (82%) 10* (3%) 323 (76%) 9* (3%) ADV (98%) 16 (8%) 9* (5%) 180 (92%) 2* (1%) 172 (88%) 3* (2%) Year Total Subjects Subjects with Viremia Subjects with Confirmed Resistance *7, 5, and 5 subjects on FTC+TDF at Yrs 3, 4, and 5 *4, 1, and 1 subjects on FTC+TDF at Yrs 3, 4, and 5 Gordon SC, et al. APASL 2012; Poster #PP Emtricitabine (FTC) is not licensed for use to treat CHB
9 Studies 102/103 Liver Fibrosis in Regression over 5 Years of Treatment with TDF Patients with Ishak score 4: 38% at Baseline, 12% at Year 5 Patients with cirrhosis (Ishak score 5): 28% at Baseline, 8% at Year 5 P<0.001 P < Percentage of patients % 39% 12% 63% Ishak Fibrosis Scores Baseline Year 1 Year 5 Marcellin P, et al. Lancet. in press.
10 Studies 102/103 Change in Ishak Scores at Year 5 for Patients with Cirrhosis at Baseline 74% (71/96) had no histologic evidence of cirrhosis (Ishak score <5) at Year 5 1% (3/252) of non-cirrhotics (Ishak score 4) progressed to cirrhosis at Year 5 (P <0.001; McNemar s test) Change in Ishak Scores at Year 5 for Patients with Cirrhosis at Baseline % of patients had 2 unit reduction n= n=15 n=41 n=14 n=1 n=24 In multivariate analysis, only low BMI was associated with fibrosis regression at Year 5 (Age, gender, origin and ALT level: no significant association) Afdhal N et al. EASL 2012, Poster 497
11 Distribution of Ishak Fibrosis Scores at Baseline and Year 5 in Lamivudine-Experienced Patients Fibrosis Score % (54/75) of LAM-experienced patients had baseline and year 5 biopsies 33% (18/54) of patients had cirrhosis (Ishak score 5) at baseline; only 4% (2/54) remained cirrhotic at year 5 Tsai N, et al. APASL 2012; Poster #PP
12 High viral load patients can achieve HBV DNA negativity with long-term TDF patients with HBV DNA >9 log 10 IU/mL (20% of overall population) 90 Percentage with HBV DNA <400 copies/ml (%) Patients with HBV DNA <400 copies/ml at week 240: Non-HVL: 99.2% HVL: 98.3% Non-high viral load (non-hvl) High viral load (HVL) Weeks on study Gordon SC et al. Hepatology 2013; doi: /hep
13 Dealing with PVR in real-life practice: Patients treated with TDF 3-year TDF in naïve CHB patients in clinical practice Outcome of patients with PVR* Patients with viraemia (%) % N= % N= % N=7 24 1% N=3 30 Months *277 patients evaluated at Month 12 Lampertico P et al. AASLD 2012; Abstract 401 (oral).
14 Long-term therapy with TDF decreased incidence of HCC vs predicted risk Data to 5 years (studies 102 and 103) HCC developed in only 8/585 patients 6 of the 8 with HCC had cirrhosis at baseline and showed no histological improvement from baseline to Week 48 6-year long-term follow-up from pivotal TDF studies compared with predicted rate of HCC using the REACH-B model Cumulative number of HCC cases Predicted Observed * Progressive divergence after 3.3 years *Standardised incidence ratio between observed and predicted was statistically significant at 5.5-year follow-up (0.55; CI: ) Years Kim WR et al. EASL 2013; Oral 43.
15 Antiviral therapy in HBeAg(+) patients with ALT <2xULN PRO Maintenance of high HBV replication increasing number of infected hepatocytes High risk of HBV transmission Patients with high HBV DNA levels are at risk of HCC regardless of ALT level Lower HBV DNA (10 4 <10 9 ) and ALT at high end of normal reflect cumulative hepatocyte damage CON Belief that there s no disease progression, minimal histological lesions Immune tolerance low probability of anti-hbe seroconversion (PEG-)ΙFN : not effective; NAs: inhibition of HBV replication Resistance during first years of therapy? Probably life-long therapy in young patients: long-term safety, patient reluctance, family planning? Zoulim F, Mason WS. Gut 2012;61: ; EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B Virus Infection. J Hepatol 2012;57:
16 Efficacy of TDF in immune tolerant patients TDF (N=64) FTC/TDF* (N=62) p value HBV DNA <400 copies/ml, % (n/n) 55 (35/64) 76 (47/62) Mean HBV DNA, log 10 copies/ml (SD) (1.46) (0.91) 0.07 HBeAg seroconversion, % (n/n) 5 (3/63) No mutations associated with TDF resistance Treatments well tolerated (2% discontinued due to AEs, 1 patient had an ALT flare associated with non-adherence) Treatment did not affect clinical endpoints, therefore no decision to treat can be made based on these data *Neither Truvada (TVD=FTC/TDF) nor emtricitabine (FTC) are licensed for use in CHB Chan HL et al. EASL 2013; Oral 101.
17 Low risk of fibrosis or fibrosis progression in immune tolerant patients Mild fibrosis (F1) detected in 50% of immune tolerant patients; no fibrosis in remainder 1 No change in fibrosis score in 42 of 48 patients who remained in the immune tolerant phase for 5 years 2 Stage Initial biopsy, n Final biopsy, n p value F F F Andreani T et al. Clin Gastroenterol Hepatol 2007;5: ; 2 Hui CK et al. Hepatology 2007;46:
18 NA characteristic in pregnancy Drug FDA pregnancy category Experience in pregnant HBV mothers Lamivudine С Two meta-analyses > 15 RCTs. Two costeffectiveness studies. Risk of birth defects No Remarks Recommended Telbivudine В Two RCTs No Recommended Tenofovir В No studies No May be recommended Entecavir С No studies In animal studies Not recommended Adefovir С No studies In animal studies Not recommended Kumar A. et al. Indian J Gastroenterol. 2012; 31 (2): 43-54
19 Tenofovir for prevention of vertical transmission of HBV in high HBV viremic pregnant women HBV DNA, log copies/ml Asian mothers received TDF at weeks of pregnancy 8,87 5,25 0/11 Baseline At delivery Infants with HBsAg+ at weeks after birth No obstetric complications or birth defect 8/11 mothers discontinued TDF 0-12 weeks postpartum without severe ALT flare Pan CQ et al., Dig Dis Sci. 2012
20 Studies 102/103 Safety Summary During the Open-Label Period By Prior Treatment Assignment TDF-TDF (n=389) ADV-TDF (n=196) Total (N=585) AEs leading to drug discontinuation, n (%) 9 (2.3) 2 (1.0) 11 (1.9) Deaths, n (%) 6 (1.5) 3 (1.5) 9 (1.5) Serious AEs, n (%) 5 (1.3) 2 (1.0) 7 (1.2) Grade 3 or 4 AEs, n (%) 3 (0.8) 3 (1.5) 6 (1.0) scr 0.5 mg/dl above baseline *, n (%) 5 (1.3) 4 (2.0) 9 (1.5) PO 4 < 2 mg/dl *, n (%) 5 (1.3) 3 (1.5) 8 (1.4) CrCl < 50 ml/min *, n (%) 3 (0.8) 3 (1.5) 6 (1.0) * Confirmed upon retest Marcellin P, et al. AASLD 2012; Boston. #374.
21 Studies 102/103 Bone Mineral Density Results from Year 4 to Year 6 Year 4 to Year 6 shifts in BMD T scores * Hip (n=294) Spine (n=308) normal osteopenia 7 patients 10 patients osteopenia normal 6 patients 11 patients osteopenia osteoporosis 2 patients 3 patients osteoporosis osteopenia 1 patient 5 patients * T score ranges: normal >-1; osteopenia -1 to -2.5; osteoporosis <-2.5 No significant changes were observed in mean BMD results from Year 4 through Year 6 for either hip or lumbar spine No consistent trends were observed in T score or Z score category shifts between Year 4 and Year 6 Marcellin P, et al. AASLD 2012; Boston. #374.
22 Conclusions Long-term TDF treatment is well tolerated and results in high rates of response (HBV DNA, HBeAg, HBsAg) without resistance development through 6 years, high rates of fibrosis/cirrhosis reversion both naїve and lamivudineexperienced patients Proportion of patients with PVR during TDF after 48 weeks depends on baseline viral load and no alteration in treatment regimen is required in the vast majority of patients Long-term antiviral therapy in the absence of resistance results in HCC reduction, but need to continue HCC surveillance even in treated cirrhotic patients! In general, patients in the immune tolerant phase do not require treatment; if signs of advanced fibrosis, treatment with TDF associated with a high genetic barrier to resistance should be considered TDF should be considered during pregnancy in high HBV DNA levels both for treatment and in third trimester for prevention of HBV perinatal transmission
Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationDisclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only
Disclaimer Presenter Release are for reactive use by Medical Information only internal learning/educational use only Any unsolicited request from HCP must be forwarded to Medical Information Housekeeping
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationUpdate on HBV Treatment
Update on HBV Treatment Calvin Q. Pan MD, FAASLD, FACG, MACP Professor of Medicine Division of Gastroenterology and Hepatology Department of Medicine, NYU Langone Health New York University School of Medicine,
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationHepatitis B: Future treatment developments
Hepatitis B: Future treatment developments VIII International Update Workshop in Hepatology Curitiba, 27.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationIs there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain
Is there a need for combination therapy? No Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain No, No and No EASL Update HBV Guidelines 2012 The most potent drugs with the optimal
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationTreatment of chronic hepatitis B 2013 update
22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationTreatment of hepatitis B : the guidelines and real life
Treatment of hepatitis B : the guidelines and real life Prince of Songkla University, Thailand Teerha Piratvisuth MD. NKC Institute of Gastroenterology and Hepatology Disclosure Statement of Financial
More informationABC of Viral Hepatitis. Mark Thursz
ABC of Viral Hepatitis Mark Thursz Disclosures Research funding Affimmune Gilead GSK Novartis Vital Therapies Advisory Boards / Speaker Fees Affimmune Norgine Novartis Gilead HAV HAV Naked RNA virus Picornavirus
More informationLandmarks for Prevention and Treatment
HBeAg-positive chronic hepatitis B Why do I treat my patient with a nucleos(t)ide analogue? Dr. Nancy Leung BSc(Lon) MSc(Lon) MBBS(Lon) MD(Lon), FRCP(Lon) FRCP(Edin) FHKCP FHKAM Consultant Physician, Alice
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationThe Evolving Landscape of Preventing Maternal-Fetal Hepatitis B Infections
The Evolving Landscape of Preventing Maternal-Fetal Hepatitis B Infections Neil S. Silverman, M.D. Center for Fetal Medicine and Women s Ultrasound Clinical Professor, Obstetrics/Gynecology David Geffen
More informationCurrently status of HBV therapy: efficacy and limitations
9 November 2016 Currently status of HBV therapy: efficacy and limitations Pietro Lampertico Gastroenterology and Hepatology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico University of
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationCurrent Status of HBV and Liver Transplant
Current Status of HBV and Liver HBV as Indication for Liver ation in U.S. Significant decrease in rate of wait listing for decompensated cirrhosis since 2003 (since s) No change in rate of wait listing
More informationShould we treat hepatitis B positive pregnant women to prevent mother to child transmission?
Should we treat hepatitis B positive pregnant women to prevent mother to child transmission? Daniel Shouval Liver Unit Hadassah-Hebrew University Hospital Jerusalem, Israel VHPB Vienna June 1-2, 2017 Background
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationHBeAg-negative chronic hepatitis B. with a nucleos(t)ide analogue?
4 th PARIS HEPATITIS CONFERENCE HBeAg-negative chronic hepatitis B Why do I treat my chronic hepatitis B patients with a nucleos(t)ide analogue? George V. Papatheodoridis, MD 2nd Department of Internal
More informationHepatitis B and D Update on clinical aspects
Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationClinical Case. Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France
Clinical Case Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France Paris, January 16th 2018 Links of interest and Disclaimer Adviser, speaker, investigator for: Abbvie, BMS,
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationGilead Sciences, Durham, NC, USA
Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF () for Treatment of Chronic Hepatitis B (CHB) In Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil: Final Week 168
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationThe Goal of HBV Therapy. Key Points. The Twin Pillars of HBV Therapy
How to Follow Once You tart Hepatitis B Treatment And When To Worry About esistance American College of Gastroenterology October 16, 21 ra Jacobson, MD Vincent Astor Professor of Medicine Chief, Division
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationHepatitis B: What You Need to Know Hepatitis B 2016
Hepatitis B: What You Need to Know 2016 Tram T. Tran MD Medical Director, Liver Transplant Fellowship Program Director Cedars Sinai Medical Center Associate Professor of Medicine Hepatitis B 2016 New Guidelines
More informationIs there a need for combination treatment? Yes!
18.0.2012 C Hep Meeting Berlin Is there a need for combination treatment? Yes! Florian van Bömmel University Hospital Leipzig Hepatology Section Germany Most patients respond to monotherapy with entecavir
More informationTerapia dell epatite cronica B: paradigmi attuali e possibili scenari futuri
Terapia dell epatite cronica B: paradigmi attuali e possibili scenari futuri Nicola Coppola Dipartimento di Salute Mentale e Medicina Preventiva Seconda Università di Napoli Main goal of treatment of chronic
More informationTreatment of hepatitis B
Treatment of hepatitis B Prof. Dr. Cihan Yurdaydin University of Ankara Medical School Department of Gastroenterology 2 nd CEE Meeting on Viral Hepatitis and Co-infection with HIV Bucharest, Romania, 6-7
More informationScottish Medicines Consortium
Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment
More informationChan HLY, Chan CK, Hui AJ, et al. Tenofovir Disoproxil Fumarate in Chronic HBV Infected Patients with Normal ALT and High HBV DNA Levels
Online supplement to: Chan HLY, Chan CK, Hui AJ, et al. Tenofovir Disoproxil Fumarate in Chronic HBV Infected Patients with Normal ALT and High HBV DNA Levels Supplementary Figure 1. CONSORT disposition
More informationtenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd
tenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd 05 August 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationFor now, do not stop NUCs PHC R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit
For now, do not stop NUCs PHC 2019 R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit Disclosure PI: Clinical Trials -ABBVIE -INTERCEPT -GILEAD -Novartis -BMS
More informationMutazioni di HBV in corso di trattamento; quale approccio razionale?
Mutazioni di HBV in corso di trattamento; quale approccio razionale? Prevenire Interpretare Trattare Marco Lagget UODU Gastroenterologia ed Epatologia AOU San Giovanni Battista di Torino Prevenire 1) Timing
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationHEPATITIS B: WHO AND WHEN TO TREAT?
HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of
More informationDon t interfere My first choice is always nucs!
Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis B Drug: Baraclude (entecavir), Epivir (lamivudine), Hepsera (adefovir), Intron A (interferon alfa- 2b), Pegasys (peginterferon alfa-2a), Tyzeka (telbivudine),
More informationWhat can the challenges we face? HBV: Long term NUC treatment
LUNCH WORKSHOP 30th January from 12:30 to 14:30 Future therapies for HBV and HDV: What can we expect? What can the challenges we face? HBV: Long term NUC treatment Massimo Levrero Cancer Research Center
More informationEpatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici. Ivana Maida
Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici Ivana Maida Positivity for HBsAg was found in 0.5% of tested women In the 70s and 80s, Italy was one of the European countries
More informationViral hepatitis in reproductive health. Pierre Jean Malè. Training in Reproductive Health Research - Geneva 2006
Viral hepatitis in reproductive health Pierre Jean Malè Training in Reproductive Health Research - Geneva 2006 15.03.2006 HBV and HCV treatment Pierre-Jean Malè MD 15.03.2006 Global Impact of Hepatitis
More informationNeed for long-term evaluation of therapy in Chronic Hepatitis B
Need for long-term evaluation of therapy in Chronic Hepatitis B VHPB meeting Budapest 18/03/2010 Solko Schalm & Mehlika Toy Licensed Therapy Chronic hepatitis B Drug Date of Efficacy Disease Clinical Mortality
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationConsiderations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection
Considerations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection Mahnaz Arian, MD Assistant Professor in infectious Disease Mashhad university of Medical
More information27/01/17. Post-partum ALT flare. HBV vaccine cannot protect all babies from high viral load carrier mothers
Trepo, Chan and Lok. Lancet 2014;384:2053-63 Prevalence High (>7%) Intermediate (2%-7%) Low (
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationManagement of HBV infection between Specialist and General Practitioners
13 October 2016 Management of HBV infection between Specialist and General Practitioners Pietro Lampertico Gastroenterology and Hepatology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico
More information2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B
David M. Fettig, M.D. Birmingham Gastroenterology Associates Outline basics of Hepatitis B Phases of Chronic Hepatitis B Evaluation of Chronic Hepatitis B Treatment of Chronic Hepatitis B Special Populations
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationHepatitis B Prior Authorization Policy
Hepatitis B Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationentecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd
entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationChronic HBV Management in 2013
Chronic HBV Management in 2013 Mohammad Hossein Somi MD Professor of Gastroentrology and hepatology Liver and Gastrointestinal Disease Research Center Tabriz University of Medical Sciences 1 HBV in 2013
More informationViral Hepatitis And Liver Transplantation
Viral Hepatitis And Liver Transplantation Dr.Zeki KARASU Ege University Medical School Dep. Gastroenterology Hepatitis B 3-7 10 % HBV infection in liver transplant recipients, in western countries. 120
More informationChronic Hepatitis B - Antiviral Resistance in Korea -
Chronic Hepatitis B - Antiviral Resistance in Korea - Young-Suk Lim University of Ulsan College of Medicine Asan Medical Center Seoul, Korea HBV Genome partially double-stranded DNA genome about 3200 nucleotides
More informationThe natural course of chronic HBV infection can be divided into four, which are not always continuous.
HEPATITIS B Hepatitis B is a major global health problem. The WHO reports that there are 350 million carriers worldwide. This disease is the leading cause of liver cancer in the world and frequently leads
More informationOur better understanding of the natural
TREATMENT OF CHRONIC HEPATITIS B: MASTERING THE BASICS ON A COMPLEX TOPIC Ke-Qin Hu, MD* ABSTRACT The availability of newer antiviral agents, as well as comprehensive treatment recommendations, has equipped
More informationBeyond the Tip of the Iceberg: Strategies to Ensure Optimal HBV Screenin g, Diagnosis, and Initial Therapy
: Strategies to Ensure Optimal HBV Screenin g, Diagnosis, and Initial Therapy Sunday, November 1, 2009 Back Bay Ballroom Sheraton Boston Hotel Boston, Massachusetts This program is supported by an educational
More informationNational Institute for Health and Clinical Excellence. Tenofovir disoproxil fumarate for the treatment of hepatitis B
National Institute for Health and Clinical Excellence Tenofovir disoproxil fumarate for the treatment of hepatitis B Comment 1: The draft remit Comments received on the draft scope Appropriateness As liver
More informationTreatment of Hepatitis B
Treatment of Hepatitis B Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Medical Director, Liver Transplantation Indiana University Health Indiana University School of
More informationClinical Case Maria Butí, MD, PhD
Clinical Case Maria Butí, MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital 1 Clinical Case 70 year-old male Smoker, no alcohol intake No risk factors Diabetes Mellitus treated with
More informationClass Update: Antivirals for Hepatitis B
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNew Approaches to Hepatitis B Therapy
ew Approaches to Hepatitis B Therapy YSGE Course 2016 Ira M. Jacobson, M.D. Chairman, Department of Medicine Mount Sinai Beth Israel Professor of Medicine Icahn School of Medicine at Mount Sinai Themes
More informationJanuary 11, 2017 NTUH. Outline
217-1-11 January 11, 217 NTUH Outline 2 3 High risk groups Persons with liver disease Persons needing immunosuppressive or cancer chemotherapy Injection drug users (IDU) Persons who have received unsafe
More informationDisclosures. Advisory Board. Honorarium, speakers bureau. Investment (stock options) BMS, Gilead, Genentech, Arrowhead. BMS, Gilead, Genentech
Advisory Board Disclosures BMS, Gilead, Genentech, Arrowhead Honorarium, speakers bureau BMS, Gilead, Genentech Investment (stock options) Arrowhead My honorarium for this meeting will be donated to recovery
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B
More informationPrimary Care for Hepatitis B and C:
Primary Care for Hepatitis B and C: Clinical Tools for Efficient Management Estimated 17 Million Persons With HCV Infection Worldwide 3-4 million newly infected each yr worldwide Advances in Internal Medicine
More informationViral hepatitis Prevention Board. Clinical aspects of hepatitis B
Viral hepatitis Prevention Board Clinical aspects of hepatitis B Natural History and serological markers acute and chronic hepatitis B Acute hepatitis B Immune response Immunological tolerance Resolution
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationTenofovir (Viread ) for the treatment of chronic hepatitis B SINGLE TECHNOLOGY APPRAISAL
Tenofovir (Viread ) for the treatment of chronic hepatitis B SINGLE TECHNOLOGY APPRAISAL Submission to the National Institute for Health and Clinical Excellence December 2008 Amended version in response
More informationNew therapeutic strategies in HBV patients
New therapeutic strategies in HBV patients Philippe HALFON MD, PhD Associate Professor of Medecine Internal Medecine and Infectious Diseases, Hopital Europeen, Marseille, France. NUC + PEG IFN, HBsAg Clearance
More informationChronic Hepatitis B. What every GP should know. Prof Ed Gane NZ Liver Unit
Chronic Hepatitis B What every GP should know Prof Ed Gane NZ Liver Unit Case 1 55 Yr old Tonga male»well but dad died of liver cancer»lfts: ALT 85, GGT 60; ALP 75; bilirubin 12 What next? Case 1 55 Yr
More informationWhite Nights of Hepatology 2016
White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow
More information